These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26979525)

  • 1. Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials.
    Zheng W; Xiang YQ; Ng CH; Ungvari GS; Chiu HF; Xiang YT
    Pharmacopsychiatry; 2016 May; 49(3):107-11. PubMed ID: 26979525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Zhang WF; Tan YL; Zhang XY; Chan RC; Wu HR; Zhou DF
    J Clin Psychiatry; 2011 May; 72(5):615-21. PubMed ID: 20868638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of extract of Ginkgo biloba as an adjunct therapy in chronic schizophrenia: A systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis.
    Chen X; Hong Y; Zheng P
    Psychiatry Res; 2015 Jul; 228(1):121-7. PubMed ID: 25980333
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wang D; Tian Y; Chen J; Zhu R; Li J; Zhou H; Chen D; Wang L; Kosten TR; Zhang XY
    Curr Neuropharmacol; 2024; 22(14):2443-2452. PubMed ID: 38919004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials.
    Savaskan E; Mueller H; Hoerr R; von Gunten A; Gauthier S
    Int Psychogeriatr; 2018 Mar; 30(3):285-293. PubMed ID: 28931444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ginkgo biloba for cognitive impairment and dementia.
    Birks J; Grimley EV; Van Dongen M
    Cochrane Database Syst Rev; 2002; (4):CD003120. PubMed ID: 12519586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M; Pigato G; Kane JM; Correll CU
    Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.
    Zhang XY; Zhang WF; Zhou DF; Chen DC; Xiu MH; Wu HR; Haile CN; Kosten TA; Kosten TR
    Biol Psychiatry; 2012 Oct; 72(8):700-6. PubMed ID: 22695185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis.
    Sun CH; Zheng W; Yang XH; Cai DB; Ng CH; Ungvari GS; Li HY; Wu YJ; Ning YP; Xiang YT
    Shanghai Arch Psychiatry; 2017 Jun; 29(3):129-136. PubMed ID: 28904507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.
    Zhang XY; Zhou DF; Zhang PY; Wu GY; Su JM; Cao LY
    J Clin Psychiatry; 2001 Nov; 62(11):878-83. PubMed ID: 11775047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of standardized Ginkgo biloba L. leaves extract as an adjuvant therapy for sudden sensorineural hearing loss: A systematic review and meta-analysis.
    Si X; Yu Z; Ren X; Huang L; Feng Y
    J Ethnopharmacol; 2022 Jan; 282():114587. PubMed ID: 34474140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [System evaluation on Ginkgo Biloba extract in the treatment of acute cerebral infarction].
    Wang L; Zhang T; Bai K
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Oct; 40(10):1096-102. PubMed ID: 26541843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Ginkgo biloba extract EGb 761 ® in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials.
    Ihl R
    Int J Psychiatry Clin Pract; 2013 Nov; 17 Suppl 1():8-14. PubMed ID: 23808613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials.
    Gauthier S; Schlaefke S
    Clin Interv Aging; 2014; 9():2065-77. PubMed ID: 25506211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial.
    Kanowski S; Hoerr R
    Pharmacopsychiatry; 2003 Nov; 36(6):297-303. PubMed ID: 14663654
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Spiegel R; Kalla R; Mantokoudis G; Maire R; Mueller H; Hoerr R; Ihl R
    Clin Interv Aging; 2018; 13():1121-1127. PubMed ID: 29942120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
    Artukoglu BB; Li F; Szejko N; Bloch MH
    J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGb 761: ginkgo biloba extract, Ginkor.
    Drugs R D; 2003; 4(3):188-93. PubMed ID: 12757407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plant-based nutraceutical interventions against cognitive impairment and dementia: meta-analytic evidence of efficacy of a standardized Gingko biloba extract.
    Solfrizzi V; Panza F
    J Alzheimers Dis; 2015; 43(2):605-11. PubMed ID: 25352453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.